I have a question for Mr. Goodman and his colleague.
A constituent in Whitby came to me within the last couple months talking about valsartan and that recall.
You talked about equalizing or normalizing the playing field for compliance audits. This is clearly a case where, in another jurisdiction, we have a product that clearly is a carcinogen that has now entered the Canadian market.
Can you explain again why it is so necessary to have that compliance to level the playing field? When you ask for a level playing field, are you asking for an increase of Canadian audits in other jurisdictions, or are you asking for a decrease in the number of audits that happen on this side?